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Tau protein in a hyperphosphorylated state makes up the intracellular inclusions of several neurodegenerative diseases, including
Alzheimer’s disease and cases of frontotemporal dementia. Mutations in Tau cause familial forms of frontotemporal dementia, estab-
lishing that dysfunctionof tauprotein is sufficient to causeneurodegenerationanddementia. Transgenicmice expressinghumanmutant
tau in neurons exhibit the essential features of tauopathies, including neurodegeneration and abundant filaments composed of hyper-
phosphorylated tau. Here we show that a previously described mouse line transgenic for human P301S tau exhibits an age-related,
layer-specific loss of superficial cortical neurons, similar to what has been observed in human frontotemporal dementias. We also show
that focal neural precursor cell implantation, resulting in glial cell differentiation, leads to the sustained rescue of cortical neurons.
Together with evidence indicating that astrocyte transplantation may be neuroprotective, our findings suggest a beneficial role for glial
cell-based repair in neurodegenerative diseases.
Introduction
Age-related neurodegenerative diseases, such as Alzheimer’s dis-
ease (AD) and frontotemporal dementias (FTDs), are increas-
ingly prevalent and there are no disease-modifying or reparative
treatments. The mechanisms underlying neurodegeneration also
remain largely unknown, although the accumulation of intracel-
lular neurofibrillary lesions composed of abnormally phosphor-
ylated and aggregated tau protein is characteristic of many
neurodegenerative disorders (Goedert and Spillantini, 2006).
Tau is a microtubule-associated protein that plays a role in regu-
latingmicrotubule assembly and stabilization, as well as in axonal
transport (Lee et al., 2001; Magnani et al., 2007). Under patho-
logical conditions tau becomes hyperphosphorylated, resulting
in its dissociation from microtubules and assembly into abnor-
mal filaments.
The identification of mutations in Tau in familial forms of
FTD (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al.,
1998) has led to the development of transgenicmodels of tauopa-
thy (Go¨tz and Ittner, 2008) that reproduce salient pathological
features of the human diseases, such as tau-containing intracel-
lular inclusions and nerve cell loss in some regions of the CNS.
However, degeneration of cortical neurons and astrogliosis, cen-
tral features of human FTD (Broe et al., 2004), have not been
reported as consistent features of these experimental models.
Accumulating evidence has suggested a role for cell-based re-
pair strategies in models of acute and chronic neuronal injury.
Embryonic and adult-derived neural precursor cells (NPCs) or
stem cells have been shown to exert beneficial effects through a
range of mechanisms. Although graft-derived neuronal differen-
tiation has been reported, only little evidence of functional neu-
ronal replacement in models of neuronal injury has been
obtained to date (Bjo¨rklund and Lindvall, 2000; Cao et al., 2001;
Hofstetter et al., 2005; White et al., 2008). Alternative neuropro-
tective pathways increasingly implicate mechanisms indepen-
dent of neuronal differentiation (Martino and Pluchino, 2006;
Lepore et al., 2008). In addition to NPCs, there is an increasing
literature that implicates a direct glial cell-mediated neuro-
protective effect in models of acute and progressive neuronal
injury throughmodification of a hostile endogenous astroglial
environment in the context of noncell-autonomous neurode-
generation (Boillee et al., 2006; Lepore et al., 2008; Yamanaka
et al., 2008).
Against this background we examined a previously character-
ized mouse line transgenic for human P301S tau for evidence of
cortical neuron loss and astrogliosis. This transgenic model has
previously been shown to accumulate hyperphosphorylated tau
in neurons within a number of CNS regions, including cerebral
cortex, amygdala, brainstem, and spinal cord, along with a neu-
roinflammatory response (Allen et al., 2002; Bellucci et al., 2004;
Delobel et al., 2008; Gasparini et al., 2009).
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In the present study we demonstrate that P301S tau mice
display progressive cortical neuron loss, especially in the su-
perficial layers, along with associated astrogliosis, and that focal
transplantation of NPCs that differentiate into glia or direct
astrocyte implantation results in sustained neuroprotection.
Materials andMethods
Animals. All procedures were performed in compliance with national
and institutional guidelines (UK Animals Scientific Procedures Act 1986
and the University of Cambridge Animal Care Committees). For charac-
terization of neuronal cell loss, female and male homozygous P301S tau
mice were killed at the onset of symptoms (Allen et al., 2002; Bellucci et
al., 2004; Delobel et al., 2008; Gasparini et al., 2009) between 4 and 6
months of age, alongwith age-matchedC57BL/6mice. Themice are only
allowed to survive to 5–6 months of age because of increasing hindlimb
disability and United Kingdom Home Office animal license regulations
requiring humane killing. For subsequent transplantation experiments,
both P301S tau and age-matched C57BL/6 male and female mice were
killed at 3 and 5 months of age. For neuronal characterization, cresyl
violet was used in n  4 P301S tau and n  4 C57BL/6 mice, while for
neuronal nuclei (NeuN) analysis n  8 P301S tau and n  7 C57BL/6
mice, respectively, were used. For the time course of NeuN and AT8
analysis, the following mice were investigated: n  5 P301S tau and
n 4 C57BL/6 mice at 2 months; n 5 P301S tau and n 3 C57BL/6
mice at 3 months; and n  8 P301S tau and n  7 C57BL/6 mice at 5
months of age.
Immunostaining and histology. Sections for immunofluorescence were
processed as described previously (Scott et al., 2005; Hampton et al.,
2008). Primary antibodies used were as follows: monoclonal anti-NeuN
(1:400, Millipore Bioscience Research Reagents); mouse monoclonal
anti-phosphotau (AT8, 1:1000, Autogen Bioclear); monoclonal anti-
GFAP (glial fibrillary acidic protein) clone GA5-Cy3 (1:500, Sigma);
monoclonal anti-neurofilamentNF200 (1:500, Sigma); polyclonal rabbit
anti-NG2 (1:500, a kind gift from Prof. W. B. Stallcup, Burnham Insti-
tute, La Jolla, CA); polyclonal rabbit-anti-Olig-2 (1:200, Millipore Bio-
science Research Reagents); polyclonal goat or rabbit anti-GFP (green
fluorescent protein) (1:1000, Abcam and Invitrogen, respectively); bio-
tinylated WFA (Wisteria floribunda agglutinin lectin) (1:200, Sigma);
rabbit polyclonal anti-GDNF (glial-derived neurotrophic factor) (1:20,
Abcam); rabbit polyclonal anti-BDNF (brain-derived neurotrophic fac-
tor) (1:100 Abcam); polyclonal anti-NGF (nerve growth factor) (1:100,
Calbiochem); monoclonal anti-Reelin (1:250, Abcam); polyclonal rabbit
anti-Cux1 (1:250, Calbiochem); and rabbit polyclonal anti-GABA (1:
500, Sigma). Secondary antibodies used were Alexa 488, Alexa 555, and
streptavidin 555 (1:500, Invitrogen) in conjunction with bisbenzamide
(1:5000, Sigma) to identify cell nuclei. Cresyl violet (Fisher Scientific)
staining was performed after serial dehydration in alcohol, followed by
brief immersion into diluted cresyl violet (0.5%) to identify neuronal cell
bodies.
Quantitative analysis. All sections were identified as being approxi-
mately equivalent to bregma, and then 0.9, 1.8 and 2.7 mm rostral of
bregma (Paxinos and Franklin, 2001). All counts and analyses were per-
formed throughout the cortex, and the cortical layers were defined as
follows: layers I and II, surface to a depth of 200 m; layer III, 200–350
m; layer IV, 350–550 m; layer V, 550–750 m; and layer VI, 750–
onwards (Rockel et al., 1980; Hill et al., 2000). We refer to the superficial
cortex throughout, and this is defined as extending from the surface to a
depth of 200 m, equivalent to layers I and II. Cresyl violet counts were
performed throughout the frontal cortex, two counts in either hemi-
sphere under a 64 160 m grid. For each animal, a minimum of three
sections per area were counted. GFP double-labeled cells were also
countedwith three slides from each animal used and aminimumof three
sections per area counted, with three 64  160 m grids counted per
section.
AT8 counts were performed under 100 500 m grids for each cor-
tical layer using three slides for each animal. Again, areas corresponding
to bregma, as well as areas 0.9, 1.8, and 2.7 mm rostral of bregma, were
identified and counts were performed such that two areas were counted
per hemisphere (lesioned side versus unlesioned contralateral side), with
a minimum of three sections per area. GABA and GFAP counts were
performed exclusively in cortical layers I and II. Counts were performed
at the same four locations relative to bregma as described above (n 2–4
sections per area).
For threshold analysis, images were captured using Lucia or Leica
software (Nikon) via a digital camera or a Zeiss AxioScope using Axio-
Vision software and SigmaScan Pro (SPSS) was used for subsequent
quantitative densitometric measurements of NeuN, bisbenzamide, and
NF200, as detailed previously (Scott et al. 2005;Hampton et al. 2008). For
NeuN and bisbenzamide, a percentage area of the cortex containing
antibody signal was generated by dividing the number of positive read-
ings by the total number of potential readings, multiplied by 100. Be-
tween four and six sections per animal were analyzed, fromwhich amean
percentage area of the cortical layer containing a positive NeuN signal
could be calculated. For NF200, once images had been set to a threshold
the density of immunopositive objects was measured independently of
their individual intensities. This allowed us to make comparisons be-
tween P301S tau, C57BL/6, and transplanted mice.
For confocal analysis, stacks of images were captured on a Leica TCS-
NT-UV confocal laser scanning microscope using a 63 1.25 numerical
aperture Leica lens or a Zeiss 720 confocal laser scanning microscope
using ZEN2009 software. Typical stacks were composed of 10–20 optical
sections of 1 m thickness taken at 0.8 m intervals. Sequential acquisi-
tions were performed in the different channels to avoid anymisinterpre-
tation of the results caused by signal cross talk.
All data were quantified using statistical analysis, including one-way
ANOVA (with the Holm-Sidak post hoc analysis) or t test, and signifi-
cance was only assumed if p 0.001.
Neural precursor cell culture. Cell culture reagents were obtained from
Invitrogen unless otherwise specified. Neonatal mice ubiquitously ex-
pressing enhanced green fluorescent protein (eGFP), a kind gift fromDr.
M. Okabe, Osaka University, Osaka, Japan (Okabe et al., 1997) were
anesthetized with ice and decapitated. Following removal of the menin-
ges, the cerebral cortex was dissociated and a single cell suspension was
generated, seeded at 1 106 per T25 flask with DMEM/F12 (Invitrogen)
containing 2% B27, 1% N2, 10 ng/ml fibroblast growth factor (FGF)-2,
and 10 ng/ml epidermal growth factor (EGF) (expansion media) and
expanded until the spheres became confluent, as described previously
(Vescovi et al., 1993; Nagahara et al., 2009). Confluent spheres were
incubated with accutase for 3 min, triturated to return them to a single
cell suspension, and reseeded into uncoated 25 cm2 flaskswith expansion
media. Spheres were passaged once before being used for transplantation
or in vitro characterization. GFP astrocytes were generated from eGFP-
NPCs treated with basal medium supplemented with bone morphoge-
netic protein 4 (BMP4) (10 ng/ml) for 96 h in the absence of EGF and
FGF-2 before harvesting for transplantation (Gross et al., 1996; Mabie et
al., 1997).
Paired samples of dissociated eGFP-NPCs were plated onto poly-D-
lysine (1 g/ml)/laminin (10 g/ml)-coated borosilicate coverslips
(5 104 cells/coverslip) corresponding to the samples used for trans-
plantation. Twenty-four hours following plating, cells were fixed with
4%paraformaldehyde.The followingantibodieswereused to stain thecells:
anti-A2B5 (1:5 supernatant, mouse IgM); anti-O4 (1:5 supernatant, mouse
IgM); anti-galactocerebroside (1:5 supernatant, mouse IgG3), anti-NG2 (1:
250, rabbit, kind gift of Prof. W. B. Stallcup); anti-microtubule-associated
protein 2 (1:500, Sigma, clone-AP-20); Tuj1 (1:500, Sigma, -III tubulin),
and anti-GFAP (1:4000, rabbit, DakoCytomation). Cell nuclei were vi-
sualized with bisbenzamide stain (Hoechst 33323, Sigma). Coverslips
were mounted on glass slides using FluroSave (Calbiochem) and viewed
under a Leica DM6000 fluorescence microscope (Leica Microsystems)
with appropriate filters for cell identification and counting. For each
coverslip, five consecutive random fieldswere examinedusing a gridwith
all cells counted. At least four coverslips were analyzed for each immu-
nostain. The number of GFP colabeled cells was expressed as amean
SEM. for each experiment (n 4).
Transplantation. eGFP-NPCs or eGFP-astrocytes were injected atrau-
matically into P301S tau and C57BL/6 male and female mice. Each ani-
mal received two injections of eGFP-NPCs (80,000 cells per injection of
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0.8 l) into the cortical gray matter (a depth of 0.4 mm, relative to the
dura) at the following coordinates from bregma: 1.0 mm mediolateral
and 1.0mmor 1.8mmanterioposterior (Franklin and Paxinos, 1997). In
experiments parallel to those of the live cell transplants, dead cells and
vehicle consisting of the controlmediawere also injected. Dead cells were
obtained by rapidly freeze-thawing eGFP-NPCs several times before
transplantation. Injections were performed on 8-week-old animals,
which were killed either 4 weeks (n  4–10 and 5–7 for P301S tau and
C57BL/6 mice, respectively) or 12 weeks after injection (n  7–10 and
4–10 for P301S tau and C57BL/6, respectively). Mice were either per-
fused with 4% paraformaldehyde or their brains were snap frozen. Per-
fused brains were cryoprotected in 25% sucrose, frozen, cut at 25mon
a cryostat, and stored at 80°C. Snap-frozen tissues were stored at
80°C and used for quantitative PCR (qPCR).
Stereology. For stereological counting of surviving eGFP-NPCs, brain
sections were stained with anti-GFP antibody. Briefly, sections were
quenched inmethanol/H2O2 and washed in PBS before blocking of non-
specific background. Sections were incubated overnight with rabbit anti-
Figure1. Neuronal cell loss in the superficial cerebral cortex ofmice transgenic for humanmutant P301S tau.A,B, Cresyl violet countswere performedon cerebral cortex of 5-month-old C57BL/6
(A) and P301S tau (B) mice (dashed lines demarcate cortical layers). C–F, Significant neuronal loss was confined to the superficial cortex (rostral of bregma) of the P301S tau mice (E, p 0.001).
Image-based threshold analysis of NeuN (Scott et al., 2005; Hampton et al., 2008) confirmed the significant loss of layer I and layer II neurons in 5-month-old P301S tau mice (C, D, F, p 0.001).
Scale bar: (in A) A–D, 200m.
Figure 2. Neuronal subtype loss and reduction in molecular marker of superficial cortical neurons in mice transgenic for humanmutant P301S tau. A, Analysis of expression of mRNAs encoding
layer-specific markers Reelin, Cux2, and ER81 by quantitative PCR showed a significant reduction in Reelin mRNA expression in transgenic mice compared with controls. B–D, Quantification of
GABAergic cells revealed a significant reduction in both 3- and 5-month-old transgenic mice compared with C57BL/6 controls ( p 0.001, arrows indicate GABA-positive cells). E–H, Immunohis-
tochemistry for the layer–specific marker Reelin revealed superficial nerve cell loss in the P301S tau mice (F , arrowheads indicate Reelin-positive cells) compared with C57BL/6 controls (E), while
no significant change inneuronal cell numberwasobserved indeeper layersusing immunostaining for eitherCux1 (G,H ) or TBR1 (Tboxbrain1) (datanot shown). Scalebars:B (forB,C),E (forE–H ), 100m.
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GFP (1:1000, Millipore Bioscience Research Reagents). They were then
washed and incubated with biotinylated anti-rabbit antibody (1:500,
Jackson ImmunoResearch Laboratories) before incubation with avidin-
biotin (Vector Laboratories). GFP labeling was revealed using 3,3-
diaminobenzidine tetrahydrochloride (DAB) and coverslips were
applied using DPX mounting medium. Stereology was performed using
an Olympus microscope with CAST-Grid program.
The GFP cells were identified anterior to bregma. The whole brain
section was first highlighted at4 objective before the areas of interest,
including the cortical layers, were defined. Sample counting windows
were identified using the computer software. The number of GFP-
positive cells in each window was counted and the fractionator method
was used to scale and approximate the number of GFP-positive cells in
each transplanted adult mouse. The following formula was used:
N   	 number ofobjects counted  1Freq  XY step areaarea of window,
where number of objects counted is the total number of GFP-positive
cells in all sections from one animal, Freq is the frequency of sections
used, the XY step area is the x step length times the y step length, and the
area of window is the area of the counting window at60magnification.
Quantitative real-time PCR. Total RNA was extracted from tissues
microdissected around the injection site using TRIzol (Invitrogen) and
PureLink RNA mini kit (Invitrogen) according to the manufacturer’s
protocol. Total RNA (2 g) was treated with RNase-free DNase I (New
England Biolabs) and reverse transcribed in 100l with random hexam-
ers using Moloney murine leukemia virus reverse transcriptase (Invitro-
gen). PCR was performed in 96-well plates using 1 l of synthesized
cDNA and forward and reverse primers [mouse (m)Reelin forward: 5-
CGAGTGGGTGAGGTGTAT-3; mReelin reverse: 5-AGCTATGCTTGAC-
CGTTGCTC-3; mCux2 forward: 5-GCGGCGTTCCTGAGTGTTTAT-3;
mCux2 reverse: 5-CTGGCAGGTGGTTACCGTT-3; hypoxanthine phos-
phoribosyltransferase (HPRT) forward: 5-TCAGTCAACGGGGGA-
CATAAA-3; HPRT reverse: 5-GGGGCTGTACTGCTTAACCAG-3])
withDyNAmoFlash SYBRGreen qPCR kit (NewEngland Biolabs) accord-
ing to the manufacturer’s protocol. Real-time PCR was performed on a
Bio-Rad iCycler as follows: 95°C for 10 min and 40 cycles of 95°C for 10 s
(denaturation) and 58°C for 45 s (annealing/extension), followed by a stan-
dardmelting curveprogram.Aminimumof threedifferent samples for each
conditionwas quantified in triplicate, and a negative control without cDNA
template was run with every assay to assess overall specificity. Quantitative
analysis of the data was performed using the iCycler analysis software. Ex-
pression levelswere normalized againstHPRTwithPCRefficiency correction.
Laser capture microdissection and quantitative PCR. Snap-frozen tissue
was cut using a cryostat (Leica) at 20 m and collected onto membrane
slides (P.A.L.M Microlaser Technologies). Tissue around GFP-positive
transplanted cells or the control region was microdissected using a Zeiss
PALM laser capture microdissection (LCM) microscope, and total RNA
was extracted using an RNAqueous-Micro LCM kit from Ambion ac-
cording to the manufacturer’s protocol. Total RNA (20–30 ng) was re-
verse transcribed using QuantiTect reverse-transcription kit from
Qiagen. GFP expression was confirmed in transplanted tissues with stan-
dard PCR (GFP forward: 5-CGACCACTACCAGCAGAACA-3; GFP
reverse: 5-GAACTCCAGCAGGACCATGT-3). cDNA from the above
reaction was used in real-time PCR without dilution. The primers were as
follows: mBDNF forward: 5-TCATACTTCGGTTGCATGAAGG-3;
mBDNF reverse: 5-AGACCTCTCGAACCTGCCC-3; mGDNF forward:
5-CACTCCTGGATTTGCTGATGT-3; mGDNF reverse: 5-AGTGT-
Figure 3. Progressive neuron loss, astrocytosis, and accumulation of hyperphosphorylated tau in the cerebral cortex of mice transgenic for human mutant P301S tau. A–E, Serial quantitative
NeuN analysis of the superficial cortex of P301S tau and C57BL/6mice at 2, 3, and 5months of age showed progressive nerve cell loss ( p 0.001). F–J, GFAP staining showed a progressive increase
in P301S tau mice compared with C57BL/6 controls. K–M, Immunohistochemistry using anti-tau antibody AT8 demonstrated the progressive accumulation of hyperphosphorylated tau in the
superficial cortex at 2, 3, and5monthsof age (dashed linedemarcates cortical layers I and II, taken1mmlateral of themidlineand rostral tobregma).AT8 stainingwent froma ring-like accumulation
at 2months (K ), through an increase in cell bodies and dendrites at 3months (L), to the presence of abundant inclusions at 5months (M ). Scale bars:A (forA–D), F (for F–I ),K (forK–M ),100m.
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GCGGTACTTGGTGC-3; mNGF forward: 5-CCAAGGACGCAGCTT-
TCTATAC-3; mNGF reverse: 5-CTGCCTGTACGCCGATCAAAA-3;
mCNTF forward: 5-TAGAGCGGCTACAGAGGTCC-3; mCNTF reverse:
5-CAAACCAGCTCACTTGTTTCC-3.
Results
Progressive superficial cortical neuron loss in humanmutant
P301S tau mice
To determine whether there was layer specificity of cortical neu-
rodegeneration, we undertook detailed quantitative neuronal
and total cell count analysis on cortices from transgenic P301S
tau and C57BL/6 control mice. Cortical neurodegeneration was
quantified using cresyl violet cell counts in both hemispheres of
brains from 5-month-old transgenic mice and age-matched con-
trols. This is the latest time point at which themice can be studied
because of the need for humane killing on account of severe
disability. A significant decrease in cresyl violet-positive cells was
observed in the superficial cortex, defined as from the surface to a
depth of 150m, in P301S tau-transgenic mice (1622 125 cells
permm2) comparedwithC57BL/6 controls (2425 495 cells per
mm2, p  0.001) (Fig. 1A,B,E). To confirm superficial cortical
neuron loss, quantification of NeuN and immunolabeling for
GABA were undertaken (Snyder et al., 1997; Park et al., 2006). A
significant reduction in the percentage area of the superficial cor-
tex containing NeuN-positive cortical neurons was observed in
P301S tau mice (10.6 6.2%), compared with controls (33.6
12.9%, p  0.001) (Fig. 1C,D,F) along with a reduction in the
number of GABAergic cells (73.9 20.8 in P301S taumice versus
339.3 44.1 in controls, p 0.001) (Fig. 2B–D). No significant
changes were observed in deeper cortical layers (Figs. 1E,F, 2D).
Quantitative PCR and immunohistochemistry of layer-specific
markers also showed a significant loss in transgenic mice of Ree-
lin, a marker of predominantly superficial layers (D’Arcangelo et
al., 1995; Shen et al., 2006; Lein et al., 2007; Molyneaux et al.,
2007), when comparedwith age-matched controls (Fig. 2A,E,F),
while Cux1 in deeper cortical layers displayed no significant
change. Together, these findings demonstrate significant neuro-
nal cell loss restricted to the superficial cortex in human P301S
tau transgenic mice at 5 months of age.
To determine the temporal progression of neurodegenera-
tion, quantitative analysis of the superficial cortex of P301S tau
transgenic and C57BL/6 control mice was undertaken at 2 and 3
months of age. NeuN analysis revealed no significant loss at 2
months (Fig. 3A,B,E, 18.4  20.9%). However, by 3 months
(45.3  12.4%, p  0.001) and 5 months (76.9  16.6%, p 
0.001) of age there was a progressive and significant loss of neu-
rons in the superficial cortex of P301S tau mice compared with
age-matched controls (Fig. 3C–E, supplemental Fig. 1A, available
at www.jneurosci.org as supplemental material). Temporal charac-
terization of staining with the phosphorylation-dependent anti-tau
antibodyAT8was also performed.We saw the staining change from
a ring-like appearance at 2months, through an increase in cell body
and dendritic staining at 3months, tomultiple, abundant tau inclu-
sions at 5months (Fig. 3K–M). This was not exclusive to the super-
ficial layers, and AT8 changes were observed in deeper layers.
In addition to progressive neuron loss, a significant increase in
the number of GFAP-positive astrocytes was observed within the
superficial frontal cortex of P301S tau mice compared with
C57BL/6 controls from 2 to 5 months of age (Fig. 3F–J, 23.3 
12.0 vs 8.3 6.1, 109.2 33.8 vs 13.1 8.9, and 156.7 33.7 v
11.7  9.3 respectively; supplemental Fig. 1B–D, available at
www.jneurosci.org as supplemental material). Serial comparisons
of brain volume and total bisbenzamide-positive cell nuclei
throughout all layers of the frontal cortex between P301S and con-
trol brains revealed no differences and, thus, confirmed progressive
neuron cell loss specific to the superficial layers (supplemental Fig.
2A–D, available at www.jneurosci.org as supplemental material).
Together, these findings reveal that P301S tau mice display
progressive, superficial cortical neuron loss with associated astro-
gliosis. Furthermore, at least a proportion of neurons containing
the ring-like tau deposits die before the formation of abundant
filamentous tau inclusions.
Figure 4. eGFP-NPCs survive, integrate, and differentiate in the cerebral cortex of mice
transgenic for human mutant P301S tau. A, B, Significant numbers of eGFP-NPCs were identi-
fied after transplantation. GFP cellswere present in cortical gray andwhitematter,migrating
along corpus callosum and cingulum (A). Stereological analysis revealed that30% of cells
had survived and integrated 1 and 3 months after transplantation (B). C–G, Following the
labeling of brain sections with several phenotypic markers, confocal microscopy was used to
examine the fate commitment of transplanted eGFP-NPCs. It was found that GFP-NPCs cola-
beledwith NG2 (C) and Olig2 (D), markers of the oligodendrocyte lineage, andwith GFAP (F ), a
marker of astrocytes (arrowheads indicate colabeled cells). Although GFP cells were found to
surround NeuN neurons and to extend processes around host NeuN cells, no evidence of
colabeled NeuN-GFP cells at either 1 month (E, and an orthogonal projection image from this
series,G) or 3months (data not shown) after transplantation was observed. Quantitative anal-
ysis of differentiation following transplantation showed that the majority of cells were GFAP
positive (69.6 4.0%),while immature oligodendrocyte differentiationwas characteristic of a
smaller number of cells (4.8 6.3%) and (17.2 2.9%) for NG2 and Olig2, respectively (H ).
Scale bars: (in A and C) A, C, D, F, 250m; (in E) E, G, 25m.
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Transplanted neural precursors and
astrocytes are neuroprotective
To test whether implantation of NPCs
may influence the progressive superficial
neuronal loss, cortices from neonatal
C57BL/6 mice ubiquitously expressing
eGFP (Okabe et al., 1997) were cultured
under substrate-free conditions in the
presence of EGF and FGF-2 (Vescovi et
al., 1993). In vitro characterization con-
firmed neuronal and glial phenotypic po-
tential of eGFP-NPCs upon plating and
withdrawal of mitogens (supplemental
Fig. 3, available at www.jneurosci.org as
supplemental material). At 2 months of
age, P301S tau mice and age-matched
controls received either live eGFP-NPCs
(8  105/l), dead eGFP-NPCs at an
equal concentration, or vehicle unilater-
ally into the cortex at 2 sites, both under 1
mm lateral of themidline, the first 0.5mm
and the second 1.8 mm rostral of bregma.
Brains were then analyzed at 1 month (3
months of age) and 3 months (5 months
of age) after transplantation.
Immunohistochemistry revealed GFP
cells in the cortical gray matter of P301S
tau mice (Fig. 4A), while stereological
analysis revealed that 30% of trans-
planted cells had survived and integrated
into host tissue, as visualized by GFP-
positive cell processes “wrapping” around
host neurons up to 3 months after trans-
plantation (Fig. 4B) in both P301S tau and
C57BL/6 mice. Phenotypic differentiation
of transplanted eGFP-NPCs was examined
by immunostaining. Although GFP cells
were observed in close proximity to endog-
enous neurons and occasionally extended
processes around them, there was no evidence of graft-derived neu-
ronal differentiation, as assessed by GFP costaining with NeuN or
doublecortin, at either 1month (Fig. 4E,G) or 3months after trans-
plantation. Themajority of GFP cells costained for GFAP, consis-
tent with an astroglial identity (Fig. 4F, 69.6  4.0%), with the
remainder costaining with NG2 (Fig. 4C, 4.8  6.3%) and Olig2
(Fig. 4D, 17.2 2.9%). Therewas no evidence of staining formark-
ers of mature oligodendrocytes, such as O4 orMBP.
Having established the exclusive glial differentiation of focally
transplanted NPCs, NeuN analysis of the superficial cortex of
both hemispheres of mice that had received unilateral delivery of
live GFP-NPCs, dead GFP-NPCs, or vehicle at 2 months of age
was undertaken. A significant increase in cortical neuronal num-
bers was observed 1 month after transplantation in the hemi-
sphere that had received GFP-NPCs compared with the
contralateral, nontransplanted hemisphere in P301S tau mice,
with no effect in C57BL/6 mice (Fig. 5A–C, p 0.001). Analysis
of both vehicle alone (Fig. 5C) and dead GFP-NPC cell trans-
plants (data not shown) showed that neither had a beneficial
effect in P301S tau mice (Fig. 5C). Transplantation of live GFP-
NPCs or dead GFP-NPCs into C57BL/6 mice had no detrimental
effect on cortical neuronal cell numbers (Fig. 5C). Following trans-
plantation of dead GFP-NPCs, NeuN analysis revealed that only
16.1 4.0% of the area of cortical layers I and II contained a NeuN
signal, whichwas comparable towhatwas observed in the contralat-
eral hemisphereofP301S taumice transplantedwith liveGFP-NPCs
(16.23.6%), the vehicle-injectedhemisphere, and its contralateral
noninjected hemisphere (16.4  6.0% and 14.4  6.6%, respec-
tively). The same was also true of the nontransplanted contralateral
hemisphere of the GFP-NPC-transplanted P301S tau mice (15.5
2.9%). A significant increase in neuronal survival was also observed
in animals killed 3months after transplantation (Fig. 5D–F).
We next examined staining for phosphorylated tau following
focal transplantation of GFP-NPCs. No cells were labeled for
both AT8 and GFP. Significantly, more AT8-positive cells were
present in the superficial cortical layers I and II of hemispheres
injectedwith eGFP-NPCs than in the contralateral hemisphere or
the hemispheres of vehicle controls (Fig. 5G–I, p  0.001). To
confirm the neuroprotective effect of NPC transplantation, im-
munolabeling forNF200,WFA, andGABAwas carried out.WFA
colocalizes with GABAergic interneurons (Ha¨rtig et al., 1992;
Bru¨ckner et al., 1993). Examination of NF200 density revealed a
significant loss of neurofilaments in P301S tau mice compared
with age-matched controls (Fig. 6A,B, D). Densitometric analy-
sis of NF200 3 months after transplantation of GFP-NPCs into
P301S tau mice showed a significant increase in density, like that
in C57BL/6 controls (Fig. 6C,D). A similar pattern was also ob-
served forWFA. (Fig. 6E,F,H). Following transplantation,WFA-
Figure 5. Transplantation of eGFP-NPCs reduces neuron loss in the superficial cortex of mice transgenic for human mutant
P301S tau. A–C, One month after transplantation (3 months of age), a significant increase in the number of neurons in the
superficial cortex was observed in the transplanted hemisphere when compared with the contralateral hemisphere, vehicle
control-injected mice, and dead cell transplants (data not shown) ( p 0.001). D–F, Similarly, 3 months after transplantation,
neuron cell numbers were significantly higher in layers I and II of the injected hemisphere when compared with the contralateral
side andwith vehicle controls ( p 0.001).G–I, Transplantation of eGFP-NPCs resulted in a significant increase in the number of
AT8-positive cells in the superficial cortex 3months after transplantationwhen comparedwith the contralateral hemisphere ( p
0.001). Scale bar: (in A) A, B, D, E, G, H, 100m.
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positive nets were significantly increased, equivalent to the levels
in C57BL/6 mice (Fig. 6G,H). Furthermore, when GABAergic
neurons were examined in brain sections from GFP-NPC-
transplanted and vehicle controls, a significant increase in the
number of GABAergic cells was observed in P301S taumice 1 and
3 months after transplantation (78.0 26.3 to 220.5 45.8 and
68.2 24.4 to 229.8 23.9, respectively, p 0.001) (Fig. 7A–E).
Quantitative PCR of cortical layer-specific markers revealed a
significant increase inReelinmRNAexpres-
sion following transplantation of GFP-
NPCs (Fig. 7F). Together, these findings
confirm a neuroprotective effect of focal
NPC implantation on the age-dependent
loss of superficial cortical neurons in
P301S tau transgenic mice.
To examine whether cell transplan-
tation resulted in a local increase in neu-
rotrophic factors as suggested by the
concept of the bystander neuroprotective
effect (Ourednik et al., 2002; Pluchino et
al., 2005), we undertook LCM and candi-
date growth factor qPCR analysis. Real-
time (RT) PCR analysis confirmed that
GFP mRNA was only expressed in the
LCM-captured, GFP-NPC transplanted
tissue and not in vehicle control samples
(Fig. 8A). Although expression of both
CNTF and GDNF mRNAs was increased
in areas containing GFP cells, only
GDNF mRNA was significantly elevated
relative to controls ( p  0.05) (Fig. 8B).
There was no increase observed in BDNF
mRNA following transplantation. The ob-
served increase in GDNF mRNA was ac-
companied by immunohistochemistry and
confocal microscopy, revealing strong
GDNF immunostaining restricted to the
GFP transplant (Fig. 8C,D). Interestingly, BDNF andNGF immu-
nohistochemistry also appeared elevated in the GFP-NPC trans-
planted mice (supplemental 4A-D, available at www.jneurosci.org
as supplemental material). These observed increases were restricted
to regions of close proximity to the GFP transplant.
To address whether the protective effect was NPC dependent
or glial dependent, we undertook unilateral focal transplantation
Figure 6. Immunohistochemistry for NF200 and WFA shows superficial cortical neuroaxonal loss and protection following transplantation of eGFP-NPCs. A–C, Confocal maximum projection
images of NF200-stained sections from 5-month-old C57BL/6mice (A), P301S taumice (B), and P301S taumice following eGFP-NPC transplantation (C).D, Quantification of NF200 using threshold
analysis demonstrated a significant decrease in density, whichwas significantly ameliorated following transplantation of eGFP-NPCs. E–H, WFA staining of cerebral cortex of C57BL/6mice (E) with
arrows highlighting examples of perineuronal nets that were lost in age-matched P301S tau transgenic mice (F ). Following transplantation of eGFP-NPCs, WFA nets were significantly increased in
number (p 0.001) (G), equivalent to what was observed in C57BL/6 mice (H ). Scale bars: A (for A–C), E (for E–G),50m.
Figure 7. A–E, Transplantation of eGFP-NPCs results in neuroprotection within the superficial cerebral cortex of mice trans-
genic for humanP301S tau. At 1 and3months after transplantation, a significant increase in thenumber ofGABAergic neuronswas
observed in the transplanted hemispheres compared with vehicle controls ( p 0.001). F, Transplantation of eGFP-NPCs also
resulted in a significant increase in Reelin mRNA expression ( p 0.05). Scale bar: (in A) A–C, 100m.
Hampton et al. • Neural Precursor-Mediated Protection from Cortical Neuron Loss J. Neurosci., July 28, 2010 • 30(30):9973–9983 • 9979
of ex vivo differentiated eGFP-astrocytes
derived from treatment of NPCs with
BMP4 (Gross et al., 1996; Mabie et al.,
1997). In vitro characterization showed
that 96.2 3.7% of cells were GFAP pos-
itive following 96 h of BMP4 treatment
(Fig. 9A). eGFP-astrocytes were trans-
planted unilaterally into the cortex of
2-month-old P301S tau mice using coor-
dinates identical to those used earlier for
the NPC transplants. Analysis at 1 month
following transplantation revealed GFP
cells located in the gray matter of trans-
genic mice (Fig. 9B). These cells were im-
munopositive for GFAP and negative for
NG2, NeuN, and AT8 (Fig. 9B,C). Hav-
ing established that eGFP-astrocytes sur-
vived and integrated into the host gray
matter and did not differentiate into neu-
rons, NeuN analysis of the superficial
cortex was undertaken. A significant
increase in the area containing NeuN
signal was found in the transplanted
hemisphere compared with the con-
tralateral, nontransplanted hemisphere
and the vehicle-injected hemisphere
(Fig. 9D,E, p  0.001).
Discussion
Our findings demonstrate a focal neuro-
protective effect of transplanted NPCs
and astrocytes in a mouse model of age-
related, layer-specific cortical neurode-
generation. Although the mechanisms
underlying neurodegeneration are un-
known, the accumulation of hyperphosphorylated filamentous
tau protein is characteristic of several human neurodegenerative
diseases, including AD and cases of FTD. Mutations in Tau
cause familial forms of FTD, establishing that dysfunction of
tau protein is sufficient to cause neurodegeneration and demen-
tia (Goedert and Spillantini, 2006).
Transgenic mice expressing human mutant tau in neurons
exhibit the essential features of tauopathies, including neurode-
generation and abundant filaments made of hyperphosphory-
lated tau protein. Our results show a significant, progressive
reduction of neurons in the superficial frontal cortex (layers I and
II) of P301S tau mice compared with age-matched controls by
using a range of quantitative morphological, histological, and
molecular outcomes. Similar to other parts of the CNS (Allen et
al., 2002; Delobel et al., 2008), human mutant tau accumulated
over time in layers I and II, became hyperphosphorylated, and
formed neuronal inclusions. Neuron loss, which was maximal at
5 months of age, the latest time point that could be studied, was
already significant in 3-month-oldmice and preceded the forma-
tion of abundant tau inclusions. Neuronal loss has been observed
in this transgenicmodel within a number of CNS regions, including
amygdala, brainstem, and spinal cord (Allen et al., 2002; Bellucci et
al., 2004; Delobel et al., 2008; Gasparini et al., 2009).
In parallel with neuron loss, we also observed an increase in
GFAP-positive astrocytes throughout the superficial cortex. This
is particularly interesting, since endogenous, reactive astrocytes
in conjunction with tau may play an important role in the pro-
gression of FTD (Broe et al., 2004; Kersaitis et al., 2004; Tan et al.,
2005). Indeed, in human cases, there is an association between
the extent of astrocytosis and the severity of disease (Broe et al.,
2004). Furthermore, cortical astrogliosis appears to precede neu-
ronal loss, suggesting an important role for astroglia in FTD
(Broe et al., 2004; Kersaitis et al., 2004).
These findings reveal for the first time thatP301S taumicedisplay
progressive neuron losswith associated astrogliosis in the superficial
layers of the cerebral cortex. This is similar to human FTD, where
postmortem examination has shown significant neuronal loss and
gliosis in the superficial frontal cortex (Rosso et al., 2001; Broe et al.,
2004; Leverenz et al., 2007; Mackenzie et al., 2008).
Accumulating evidence has implicated cell-mediated neuro-
protection through a variety of mechanisms ranging from cell
replacement to growth factor-mediated functional recovery
(Martino and Pluchino, 2006; Lepore et al., 2008, Barhum et al.,
2010). Previous studies using a tetracycline-inducible promoter
to focally ablate neurons in the hippocampus have demonstrated
a significant reduction in NeuN cells in the CA1 region with
evidence of functional improvement following focal transplanta-
tion ofNPCs (Yamasaki et al., 2007). Furthermore, a recent study
in a transgenic mouse model of AD exhibiting hippocampal syn-
aptic dysfunction revealed functional improvement following fo-
cal NPC transplantation, accompanied by increased synaptic
density mediated by increased production of BDNF (Blurton-
Jones et al., 2009). This is of interest given that in the current
study we observed an increase in neurotrophins, particularly
GDNF, following transplantation of eGFP-NPCs. To examine
whether focal implantation of neural populations may influence
Figure8. Quantificationof expressionofGDNF following transplantationof eGFP-NPCs.A,B, LCMand semiquantitativeRT-PCR
were used to identify GFP cells following transplantation. GFP mRNA was only detected in LCM samples from eGFP-NPC-
transplanted P301S tau mice (A). HPRT was used as a loading control. Transplantation of eGFP-NPCs resulted in a significant
increase in GDNF mRNA ( p 0.05) compared with control samples, as measured by quantitative PCR following LCM (B). C, D,
GDNF immunohistochemistry showing amaximumprojection image of GDNF, GFP and bisbenzamide following transplantation of
eGFP-NPCs (C) and an orthogonal projection image (D) from this series showing GFP-positive processes located around an area of
increased GDNF staining. Scale bars: C, D, 40m.
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neuron loss in our model, we undertook focal transplantation
studies. In vitro characterization confirmed the trilineage neuro-
nal and glial phenotypic potential of eGFP stem cells (Vescovi et
al., 1993; Webber et al., 2007). Following transplantation of
eGFP-NPCs, we observed glial differentiation without graft-
derived neuronal differentiation at 1 and 3 months after trans-
plantation, consistent with previous studies using injury
paradigms (Cao et al., 2001, 2002; Hofstetter et al., 2005;Webber
et al., 2007; White and Jakeman, 2008). We demonstrate that
following unilateral focal transplantation of eGFP-NPCs, super-
ficial cortical neurons are protected from neurodegeneration,
with transplanted NPCs being able to counteract the neurotoxic
effects of misfolded tau. This was not a consequence of cell re-
placement, as no evidence of neuronal differentiation was ob-
tained. We present several lines of evidence to demonstrate a
neuroprotective effect of NPCs within the superficial cortex, in-
cluding multiple nerve cell counts and analyses at both 1 and 3
months after transplantation. In addition, the finding that after 3
months P301S taumice had significantlymore AT8-positive cells
per mm2 in the superficial cortex of hemispheres injected with
eGFP-NPCs suggests that transplanted NPCs exert a neuropro-
tective effect independently of the progressive accumulation of
hyperphosphorylated tau. The exclusively glial, predominantly
astrocytic differentiation of grafted NPCs suggests that the neu-
roprotective effect of NPCs is glial dependent. To address this
hypothesis, astrocyte transplantation was undertaken. Focal
transplantation of ex vivo NPC-derived astrocytes that integrate
and differentiate only into GFAP cells also resulted in a neuro-
protective effect of superficial cortical neurons, a finding consis-
tent with a glial-mediated neuroprotective effect of cell
transplantation.
The precise mechanisms underlying the neuroprotection ob-
served in our study are unknown. The comparable effects of
transplantation of NPCs that differentiate into astrocytes and of
direct astrocyte transplantation suggest that graft-derived astro-
cytesmediate the protective effect in P301S taumice. This finding
is consistent with recent studies that have reported an astroglia-
mediated neuroprotective effect in different models of neuronal
injury (Boucherie et al., 2009; Davies et al., 2006, 2008; Lepore et
al., 2008). In view of the accumulating evidence suggesting a
role for astrocytes in noncell-autonomous neurodegeneration
(Boillee et al., 2006; Yamanaka et al., 2008), one interpretation is
that exogenous astrocytes are improving a hostile glial environ-
ment. The concept of astrocytes being injurious or protective de-
pending on context is supported by a growing literature (Davies et
al., 2008; Lepore et al., 2008). This idea has gained support from
a study showing that focal astrocyte transplantation exerted a
neuroprotective effect with functional improvement in trans-
genic rats expressing human mutant superoxide dismutase-1
(SODG93A) (Lepore et al., 2008). The beneficial effect was, in part,
mediated by the primary astrocyte glutamate transporter GLT1.
Additional putative glia-mediated neuroprotective mechanisms
suggested from spinal cord injury transplantation studies include
immune modulation, suppression of proteoglycan inhibition,
and secretion of neurotrophic growth factors (Davies et al., 2006;
Boucherie et al., 2009). In this regard, our finding of an increase
in neurotrophins in regions containing GFP transplanted cells,
similar to the “bystander” effect observed in previous studies of
neural stem cell populations, is of interest (Ourednik et al., 2002;
Pluchino et al., 2005; Martino and Pluchino, 2006; Nagahara et
al., 2009). The observed increase in neurotrophins following
transplantation suggests local graft-mediated growth factor de-
livery as a potential explanation for the observed neuroprotec-
tion. Indeed, direct administration of BDNF in a rodentmodel of
AD exerts substantial protective effects, leading to reduction in
synaptic loss and restoration of learning and memory (Nagahara
Figure 9. Transplantation of eGFP-astrocytes reduces neuron loss in the superficial cortex of mice transgenic for human P301S tau. A, GFP-NPCs were derived and differentiated into astrocytes
using BMP4, followed by transplantation into P301S tau mice. B, C, Following unilateral transplantation, GFP astrocytes were identified within the gray matter of P301S tau mice and found to
express the astrocytic marker GFAP (arrowheads indicate GFP-positive astrocytes). D–F, One month after transplantation, a significant increase in nerve cell numbers in the superficial cortex was
observed in the transplanted hemisphere, when compared with the contralateral hemisphere and to vehicle controls ( p 0.001). Scale bars: (in A, C, D) A–E, 100m.
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et al., 2009). Another potential mechanism for the neuroprotec-
tive effects of both the glial-derivedNPC transplant and the direct
astrocytes may be through secretion of activity-dependent neu-
roprotective protein (ADNP). Recent literature suggests this
protein is secreted by astrocytes, while intranasal delivery of a
peptide fragment derived from ADNP, termed NAP, has been
demonstrated to increase soluble tau, reduce hyperphospho-
rylation, and reduce cognitive decline observed in tau trans-
genic mice (Furman et al., 2004; Shiryaev et al., 2009). This
mechanism may be an additional effect that the exogenous
transplanted astrocytes have on the endogenous populations and
thus promotes neuroprotection.
In conclusion, the present study reports that exogenous NPCs
and astrocytes exert a powerful neuroprotective effect in a novel
model of progressive age-related, layer-specific, cortical neuro-
degeneration caused by dysfunction of tau protein. Our findings
provide an important platform for exploring the mechanisms of
glia-mediated neuroprotection and have significant implications
for the development of future treatment strategies for neurode-
generative disorders, such as AD and FTD.
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